Shared Decision Making in EGFR-Mutant Advanced NSCLC

Panelists discuss the shared decision-making process following Melinda's evaluation, with Dr. Spira explaining the factors that led to recommending the MARIPOSA2 regimen, while Melinda shares her active role in participating in the decision-making process regarding her treatment.

EP: 1.Overview of EGFR-Mutant Advanced NSCLC

EP: 2.EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians

EP: 3.Coordinating Care for Patients with Advanced EGFR-Mutant NSCLC: A Multidisciplinary Approach

EP: 4.Multidisciplinary Care of EGFR-Mutant Advanced NSCLC: A Patient Perspective

EP: 5.Tailoring Patient Education and Resources in EGFR-Mutant Advanced NSCLC

EP: 6.Navigating EGFR-Mutant Advanced NSCLC Cancer Treatment: A Patient's Journey

Now Viewing

EP: 7.Shared Decision Making in EGFR-Mutant Advanced NSCLC

EP: 8.Preparing Patients for Treatment: Education, Administration, and Side Effect Management with Amivantamab in EGFR-Mutant NSCLC

Video content above is prompted by the following:

• Following Melinda’s evaluation, how did the shared decision-making process unfold, and what factors ultimately led you to recommend the MARIPOSA2 regimen?
• How did you participate in the shared decision-making process for your treatment?

Recent Videos